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Background: Tight control of disease activity, medication side effects, and adherence are crucial to prevent disease complications and improve quality
of life in patients with inflammatory bowel disease (IBD). The chronic nature and increasing incidence of IBD demand health care innovations to
guarantee future high-quality care. Previous research proved that integrated care by telemedicine can improve outcomes of chronic diseases. Currently
available IBD telemedicine tools focus on specific patient subgroups. Therefore, we aimed to (1) develop a telemedicine system suitable for all patients
with IBD in everyday practice and (2) to test this system’s feasibility.
Methods: With a structured iterative process between patients, dietitians, IBD nurse-specialists, and gastroenterologists, myIBDcoach was developed.
During 3 months, myIBDcoach’s feasibility was tested by 30 consecutive outpatients with IBD of 3 hospitals. Thereafter, patients and health care
providers completed a questionnaire covering satisfaction, accessibility, and experiences with myIBDcoach.
Results: MyIBDcoach enables continuous home-monitoring of patients with IBD and optimizes disease knowledge and communication between
patients and health care providers. Besides disease activity, medication adherence, and side effects, myIBDcoach monitors malnutrition, smoking, quality
of life, fatigue, life-events, work participation, stress, and anxiety and depression and provides e-learnings for patient empowerment. Patients graded the
system with a mean of 7.8 of 10, and 93% would recommend myIBDcoach to other patients.
Conclusions: We developed myIBDcoach, which enables integrated care for all patients with IBD, regardless of disease severity or medication use.
The feasibility study showed high satisfaction and compliance of patients and health care providers. To study myIBDcoach’s efficacy, a multicenter
randomized controlled trial has been initiated.
(Inflamm Bowel Dis 2017;23:485–493)
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I nflammatory bowel disease (IBD) is a chronic disorder of thegastrointestinal tract with a peak onset in early adulthood.1 Crohn’s
disease (CD) and ulcerative colitis (UC) are the 2 main subtypes, but
within these groups the clinical presentation is very heterogeneous
with regard to disease location, disease behavior, occurrence of ex-
traintestinal manifestations, and therapy response.2 IBD has a signif-
icant impact on quality of life (QoL) and constitutes an economic
burden because of direct and indirect health care costs.3–5
Recent studies show that tight control of disease activity
and early interventions in case of recurrence of intestinal
inflammation are important to shorten flare duration and prevent
complications.6 Furthermore, most available drugs are immuno-
suppressives which can have severe side effects.7,8 For these rea-
sons, continuous and personalized monitoring of patients with
IBD with regard to disease activity, medication use, and side
effects is required. In addition, many aspects that may influence
disease activity, such as stress, smoking, nutritional status, and
treatment adherence are not followed systematically in most IBD
clinics. Interventions on these aspects may significantly improve
the long-term outcome of IBD.9,10 Furthermore, systematic regis-
tration of patient-reported outcome measures (PROMs) and work
disability is increasingly requested by health care insurers to
guarantee reimbursement of expensive drugs, whereas patients
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themselves also demand empowerment and more involvement
with their therapy.
Continuous monitoring of this multifaceted, chronic, and
invasive disease, given the increasing incidence of IBD,11–13 will
put significant pressure on gastrointestinal health care capacities.
To guarantee personalized, high quality, efficient, and affordable
health care for patients with IBD in the future, innovative solu-
tions are warranted.
Health care at a distance, also known as telemedicine or
eHealth, is a possible innovation that may contribute to the quality
and efficiency of care for patients with IBD.12,14,15 eHealth has
already been implemented successfully for several other chronic
diseases, such as congestive heart failure,16,17 asthma,18 hyperten-
sion,19 chronic obstructive pulmonary disease,20,21 and diabetes
mellitus.22,23 Mounting evidence shows that direct involvement of
health care providers, promotion of patient empowerment and
integrated care improve the outcome of chronic diseases.24–27
Also for patients with IBD, several telemedicine systems have
been developed. Cross et al developed a Home Telemanagement
System for patients with UC,28–32 composed of a netbook computer
and an electronic weight scale that monitors symptoms, medication
usage, and side effects. Elkjaer et al developed a web-based system
(Constant Care) to monitor disease activity and QoL in patients with
mild-to-moderate UC on 5-aminosalicylic acid (5-ASA) treat-
ment.26,33 This program was also used for individualization of
5-ASA treatment and improvement of adherence in mild-to-
moderate patients with UC10 and for individualization of infliximab
(IFX) scheduling in patients with CD on IFX maintenance
treatment.34
Overall, these systems were shown to be feasible, safe, and
well accepted by patients with IBD,35,36 but are developed for
subgroups of patients with IBD with relatively mild disease.
Therefore, we aimed (1) to develop a telemedicine system for
all subtypes of patients with IBD in everyday clinical practice
through close collaboration of patients, IBD nurse-specialists,
and gastroenterologists using a structured approach and (2) to test
the feasibility of this system in terms of compliance and satisfac-
tion among patients and health care providers.
MATERIALS AND METHODS
Development of MyIBDcoach
Design and Content Development
Before the start of the development phase, the need for an
integrated eHealth system for patients with CD in the Netherlands
was evaluated among different stakeholders, i.e., patients with IBD
from the Dutch IBD patients’ organization,37 dietitians, representa-
tives from the pharmaceutical industry, gastroenterologists, and IBD
nurse-specialists from academic as well as nonacademic hospitals
(Fig. 1, phase I). Subsequently, they discussed the design of the
telemedicine program further called as myIBDcoach, the relevant
topics, and questionnaires to be included as well as safety
management of home-monitoring using a structured iterative process
(Fig. 1, phases II–V). In addition, topics for e-learning modules were
selected and subsequently developed by topic-specific experts and
reviewed by an independent gastroenterologist (Fig. 1, phase VI).
To facilitate broad support and implementation of myIBD-
coach and to improve cooperation between the various stake-
holders, a foundation was instituted.38 The director of the Dutch
IBD patients’ organization, 2 gastroenterologists, an accountant,
and an assistant professor of health analytics systems constitute
the board. Representatives of the aforementioned stakeholders as
well as those of the IBD section of the Dutch Association for
Gastroenterology (NVGE), the Dutch Association for Gastroen-
terologists (NVMDL), and the Association of IBD Nurse Special-
ists (N-NIC) form a separate committee which decides on the
design and content of myIBDcoach.
Technological Development
The technological development of myIBDcoach was con-
ducted by Sananet BV,39 specialized in development and imple-
mentation of telemedicine and self-management tools. They
integrated relevant information and questionnaires into both
a web-based and an HTML application and created a secure link
between patients and the hospital.
The system includes so-called monitoring modules, intensi-
fied monitoring modules, outpatient visit modules, e-learning
modules, a plan, and an administrator page used by the health
care provider (Fig. 2). The modules will be discussed in detail later.
MyIBDcoach meets all legal requirements in line with the European
laws regarding security and confidentiality of patient data.
Feasibility Study of MyIBDcoach
After the technological and content development, a feasibility
study was planned in 3 clinical centers to evaluate compliance,
satisfaction, accessibility, and experiences with myIBDcoach from
both health care providers and patients.
From November 2012 until March 2013, 30 patients were
recruited from the tertiary referral centers Maastricht University
Medical Center+ and Leiden University Medical Center, and from
the nonacademic hospital Zuyderland Medical Center. Patients
between 18 and 75 years of age, fulfilling the international diagnos-
tic criteria for IBD,40 were eligible for inclusion. Exclusion criteria
consisted of inability to read or understand the informed consent
form, lack of internet access by computer, tablet, or smartphone, or
lack of a hospital admission because of IBD disease activity within
2 weeks before inclusion because of practical reasons.
Participating patients followed a short practical training on
how to use myIBDcoach. After this, participants received a unique
username and password and were asked to log on to http://www.
mijnibdcoach.nl. During a 3-month study period, patients were
requested to complete the myIBDcoach monitoring module
monthly. At the end of the study period, patients and health care
providers from the participating hospitals were asked to fill out an
evaluation questionnaire regarding satisfaction, accessibility, and
experiences with myIBDcoach.
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Ethical Considerations
The study was approved by the Medical Research Ethics
Committee of the Maastricht University Medical Center (METC
azM/UM), which waived the requirement to obtain inform
consent. The study protocol conformed to the provisions of the
declaration of Helsinki.
Data Collection and Outcome Measures
Feasibility data in terms of satisfaction, accessibility, and
experiences with myIBDcoach were collected from patients’ and
health care providers’ evaluation questionnaires. Compliance
with myIBDcoach in this pilot study was predefined as $70%
adherence with the monthly monitoring modules. Demographic
information was obtained from all patients at the time of
recruitment.
Statistical Analyses
Descriptive analyses to evaluate demographic information
and to assess feasibility with myIBDcoach were performed using
IBM SPSS statistics 22.0.
FIGURE 1. Different phases of design and content development of myIBDcoach.
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A personal web-based telemedicine system for patients with
IBD, myIBDcoach, was designed and developed as a secure webpage
(http://www.mijnibdcoach.nl) and HTML application on a tablet or
smartphone (Fig. 3). MyIBDcoach can be used as a stand-alone pro-
gram; however, incorporation in different hospital electronic patient
files is technically also possible. Sananet BV provides technical sup-
port for all participants (patients and health care providers).
Content Development
During the first brainstorm meeting with the identified
stakeholders (Fig. 1, phase II), patients emphasized the importance
of better communication with the hospital, tailored information
about their disease and medication, as well as patient-centered care.
Gastroenterologists noticed that a more holistic approach to the
patient with IBD was needed, since many disease-related aspects,
including nutrition, work productivity, smoking, and anxiety and
depression were often not addressed in the current practice, but are
of relevance for disease outcome and health-related QoL. Further-
more, the importance to monitor disease activity and side effects of
(immunosuppressive) drugs was emphasized. Both gastroenterolo-
gists and the representatives from the pharmaceutical industry indi-
cated better monitoring of therapy adherence to be of relevance to
optimize treatment. Home-monitoring of disease activity and
disease-related aspects at regular intervals requires validated
PROMs, which are also demanded by governments for registration
of efficacy endpoints for expensive drugs.
FIGURE 2. Schematic overview of different functions of myIBDcoach: monitoring, personal care plan, e-learning modules, and communication. An
overview of content and frequency of modules is shown in Table 1. When values recorded from the questions of the monitoring modules exceed
predefined thresholds, alerts (red flags) are created in the back-office.
FIGURE 3. MyIBDcoach.
de Jong et al Inflamm Bowel Dis  Volume 23, Number 4, April 2017
488 | www.ibdjournal.org
Copyright © 2017 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
Based on the literature review, validated PROMs on
medication adherence, medication satisfaction, nutritional status,
QoL, work productivity, anxiety and depression, social support,
and fatigue were selected. When different validated question-
naires on the same topic were available in the literature, the
shortest applicable questionnaire was chosen if there were no
major advances of the other questionnaires, to constrain moni-
toring modules to a reasonable length.
Validated PROMs for disease activity and infectious events
were not available in the literature (Fig. 1, phase III). Existing
patient-reported disease activity questionnaires, such as the
patient Harvey Bradshaw index and the patient simple clinical
colitis activity index, are not validated against endoscopy and
show poor correlation with endoscopic disease activity.41–44
Therefore, myIBDcoach uses a newly developed Monitor IBD
At Home questionnaire (MIAH)45 (Fig. 1, phase IV). This is
a symptom-based PROM that is validated against endoscopy
and does not require laboratory tests or physical examination.
The MIAH shows good diagnostic accuracy to screen for patients
who need further assessment of disease activity with biochemical
markers, imaging, or endoscopy,45 and excellent accuracy when
combined with a home calprotectin test.46 A score of #3.6 is
defined as remission. In addition, a new questionnaire on medi-
cation side effects and infectious events was developed.
A schematic overview of the design of myIBDcoach is
shown in Figure 2 and an overview of questionnaires as well as
their frequency of monitoring is given in Table 1.
Monitoring Module
Patients are requested to complete the regular “monitoring
module” monthly, which contains questions regarding disease
activity (MIAH),45 extraintestinal manifestations, medication
use, medication adherence (Morisky Medication Adherence
Scale47), satisfaction (Treatment Satisfaction Questionnaire for
Medication48) and side effects including infections. In addition,
the monitoring module measures general disease aspects as QoL
(euroQol instrument51 and Short Form Health Survey52), work
productivity (Work Productivity and Activity Impairment
[WPAI53]), nutritional status (Malnutrition Screening Tool49
and Short Nutritional Assessment Questionnaire50), fatigue,
physical exercise, stress, life-events, anxiety and depression,
social support, and self-management skills. When the disease
is in remission, defined as 3 consecutive MIAH-scores #3.6,
patients will be asked if they prefer to fill out the monitoring
module once per 3 months. In case of a flare, defined as a MI-
AH-score .3.6, patients are requested to log on weekly and
complete the “intensified monitoring module” on disease activ-
ity and medication use until the symptoms subside.
TABLE 1. Design of myIBDcoach
Section Function Frequency
Monitoring module 1. Monitors patient-reported disease activity (MIAH45), extraintestinal
manifestations, medication use, adherence (Morisky Medication Adherence
Scale47), satisfaction (Treatment Satisfaction Questionnaire for
Medication48) and side effects
Monthly or every 3 months
when sustained remission
2. Monitors general disease aspects: nutritional status (Malnutrition Screening
Tool49 and Short Nutritional Assessment Questionnaire50), QoL (euroQol
instrument51, SF-1252), work productivity (WPAI53), infections and single
questions on fatigue, physical exercise, stress, life-events, anxiety and
depression, social support, and self-management skills.
Intensified monitoring module Monitors patient-reported disease activity (MIAH45) and medication usage in
case of a flare.
Weekly
Outpatient visit module Registers patient-reported disease activity (MIAH45), extraintestinal
manifestations, QoL (Short Inflammatory Bowel Disease Questionnaire54),
smoking, work productivity (WPAI53), intimacy and sexuality, anxiety and
depression (Hospital Anxiety and Depression Scale55), medication
adherence, nutritional status (Malnutrition Screening Tool49 and SNAQ50),
social support (social support list56) and fatigue (shortened fatigue
questionnaire57), and a topic patients would like to discuss with their health
care provider during the upcoming outpatient visit.
Yearly/when applicable
E-learning module Offers patient-tailored information on 16 selected topics. When applicable
Communication Facilitates communication between patient and health care provider and
provides systematic documentation of communication.
24/7 available
Personal care plan Gives a clear overview of follow-up for both patient and health care provider. 24/7 available
MIAH, Monitor IBD At Home; MMAS-8, Morisky Medication Adherence Scale; TSQM, Treatment Satisfaction Questionnaire for Medication; MST, Malnutrition Screening Tool;
SNAQ, Short Nutritional Assessment Questionnaire; EQ-5D, EuroQol instrument; SF-12, Short Form Health Survey; WPAI, Work Productivity and Activity Impairment; SIBDQ, Short
Inflammatory Bowel Disease Questionnaire; HADS, Hospital Anxiety and Depression Scale; SSL, Social Support List; SFQ, Shortened Fatigue Questionnaire.
Inflamm Bowel Dis  Volume 23, Number 4, April 2017 MyIBDcoach: A Telemedicine Tool for IBD Patients
www.ibdjournal.org | 489
Copyright © 2017 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
Back-Office
The administrator page, further called as back-office, is used
by the patient’s own health care provider, i.e., a gastroenterologist or
an IBD nurse (specialist), and provides an overview of all partici-
pating patients per center. As myIBDcoach is a self-management
system, patients are in the lead to contact the health care provider in
case of symptoms or other questions. To ensure safety of home-
monitoring, alerts (red flags) are created in the back-office when
values recorded from the questions of the monitoring module exceed
predefined thresholds. In case of an alert, the health care provider
will contact the patient for further evaluation. Based on the extent
and severity of the complaints, they decide whether the patient
should be seen at the outpatient clinic. At any time, patients can
communicate easily with their health care provider by sending a mes-
sage through the secure connection to the back-office of the health
care provider. Every new message creates an alert in the back-office.
Outpatient Visit Module
When a routine outpatient visit is scheduled, patients are
asked to prepare this visit by completing the “outpatient visit
module,” which registers patient-reported disease activity
(MIAH),45 extraintestinal manifestations,58 and parameters which
may influence long-term disease outcomes such as QoL (Short
Inflammatory Bowel Disease Questionnaire54), smoking, work
productivity (WPAI),53 intimacy and sexuality, anxiety and
depression (Hospital Anxiety and Depression Scale55), medica-
tion adherence, social support (Social Support List56), and fatigue
(shortened fatigue questionnaire57). The values recorded from
these questionnaires are presented in a clear overview to make
the consultation with the gastroenterologist as efficient as possible
and to make sure all relevant topics will be discussed and patients
will be referred to other specialists when necessary. Furthermore,
patients are given the opportunity to note what they would like to
discuss with their health care provider during the visit.
E-Learning Modules
To improve patients’ knowledge on IBD, we developed
patient-tailored interactive e-learning modules about CD and
UC in general, mesalamines, immunosuppressives or anti–tumor
necrosis factor therapy, medication adherence, smoking cessation,
(mal)nutrition, how to prevent or reduce symptoms (self-
management), fatigue, work productivity, pregnancy, intimacy,
anxiety and depression, influenza vaccination, and about how to
receive adequate support from friends, family, and colleagues
(Fig. 1, phase VI). Both patients and health care providers can
start an e-learning module, i.e., patients can be advised to perform
a certain e-learning module whenever their health care provider
considers it desirable or when the patients themselves are
interested in a specific topic.
Self-Management
All information derived from the monitoring and outpatient
visit modules is presented in a personal care plan. The personal
care plan summarizes all disease aspects in tables and graphs for
both the patient and the health care provider (Fig. 4). By pro-
viding insight in their personal care plan, we aim to improve
patients’ self-management and stimulate patient empowerment.
Results Feasibility Study of MyIBDcoach
MyIBDcoach was pilot-tested in 30 patients with IBD and
8 health care providers. Patient characteristics are shown in
Table 2. Compliance with the monthly monitoring modules was
100%. Patients judged myIBDcoach with a mean score of 7.8 of
10, and health care providers gave a mean score of 8.0 of 10. Both
patients and health care providers found the design and accessi-
bility of the system of high quality. One patient thought that the
system was time-consuming. Ninety-three percent of the patients
would recommend myIBDcoach to other patients.
During the 3-month study period, 40% of the patients (n ¼
12) contacted their health care provider through myIBDcoach for
urgent symptoms or general questions. Of these patients, 83%
found that this contact had a positive contribution to the overall
contact with their health care provider. Ninety percent of the
patients completed at least 1 e-learning module. After completing
the e-learning modules, most these patients felt that their general
knowledge about their disease had improved.
DISCUSSION
This article describes the systematic development of the first
telemedicine system that enables home-monitoring for all subtypes
of patients with IBD. A pilot study proved that myIBDcoach is
feasible for use in routine care and is well accepted by patients and
health care providers. Patients were compliant with the program,
indicated that myIBDcoach facilitated communication with their
health care providers and that the e-learning modules improved
their knowledge about IBD.
During this pilot study, adherence to the system was very
high. In the literature, telemedicine tools faced attrition rates as high
as 14% to 44% over time.10,15,26,30,34 We aimed to increase com-
pliance with myIBDcoach by involving patients in all stages of the
development, by providing feedback to the patient in a personal
care plan and by constraining questionnaires to a reasonable length
with individualized frequency. To increase patient empowerment,
myIBDcoach contains e-learning modules, promotes patients’ self-
management, and facilitates communication between patients and
health care providers. The finding that 93% of patients would rec-
ommend myIBDcoach to other patients reflects a high patient sat-
isfaction rate. Additionally, to enhance user friendliness,
myIBDcoach can also be used on a smartphone or tablet.
Despite proven benefits of telemedicine for IBD and other
chronic diseases, few systems are implemented in everyday care.
One possible reason might be that previously published tools
monitor, educate, or empower specific groups of patients10,26,30,34
(Table 3). Contrary to this, we deliberately designed myIBDcoach
for all subtypes of patients with IBD in different settings, regardless
of phenotype, disease activity, or medication use. In addition, we
wanted myIBDcoach to focus on all facets of this complex disease,
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i.e., not only directly on IBD-related aspects, but also on stress,
smoking, nutritional status, and treatment adherence, which may
impact disease outcome and QoL. Prevention of treatment nonad-
herence for example, reported to be as high as 40% to 60% in
patients with IBD, has a significant impact on the risk of disease
relapse, hospitalization, health care costs, and work absenteeism.9,10
Jackson et al15 recently reviewed the entire spectrum of
eHealth interventions used for IBD management and provided
recommendations for the design of future IBD eHealth technolo-
gies to facilitate implementation. They emphasized the impor-
tance of a framework for development, evaluation, and
implementation of eHealth interventions and the relevance of
patient and clinician involvement in all stages. MyIBDcoach
was developed through close collaboration between patients,
nurses, and gastroenterologists during all phases of the develop-
ment. The rights for the content of the system are governed by
a nonprofit foundation. The board and content committee of the
myIBDcoach foundation consist of patients and clinicians from all
important Dutch stakeholders involved in IBD care. The founda-
tion carefully monitored all phases of the developmental and im-
plementation process.
As the pilot study showed that IBD care with myIBDcoach is
feasible and can be used for routine follow-up, we initiated
TABLE 2. Baseline Characteristics of the Participating
Patients in the Feasibility Study
Participating Patients (n ¼ 30)
Age, mean (SD) 44.2 (11.7)
Gender, N (%)
Male 12 (40.0)




FIGURE 4. Personal care plan of myIBDcoach.
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a randomized controlled trial to investigate whether the integrated
and holistic approach of myIBDcoach is safe and increases
efficiency of IBD care compared with that of standard care. A total
of 909 consecutive outpatients with IBD from academic and
nonacademic hospitals, regardless of disease severity and activity,
and treatment strategies ranging from no treatment to combined
immunosuppressives, were included and randomized to care by
means of myIBDcoach or standard care for 1 year. The primary
endpoints are the number of outpatient visits and patient-reported
quality of IBD health care. Secondary endpoints include disease
outcomes (i.e., flares, corticosteroid use, hospitalizations, emergency
visits, and IBD-related surgery), medication adherence, and QoL.
We will also assess whether use of myIBDcoach leads to patient
empowerment by an increase in knowledge about the disease and
treatment and whether myIBDcoach is a suitable tool for structured
collection of PROMs.
In conclusion, we developed myIBDcoach, which enables
integrated and holistic care for all patients with IBD in both
academic and nonacademic centers. The feasibility study showed
high satisfaction of patients and health care providers with the
system. After these positive results, a large multicenter random-
ized controlled trial has been initiated.
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